



INVESTOR PRESENTATION

JANUARY 2019





FORWARD LOOKING STATEMENTS

Safe Harbor Statement

This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believe,” “hopes,” “intends,” “estimates,” “expects,” “projects,” “plans,” “look forward to,” “anticipates” and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. These forward-looking statements are not guarantees of performance and actual results could differ materially from those contained in such statements. These forward-looking statements are based on our current expectations and beliefs concerning future events affecting us and involve known and unknown risks and uncertainties that may cause our actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties are discussed in greater detail in our Annual Report on Form 10-K and Quarterly Report on Form 10-Q under the caption “Risk Factors” and in other documents filed by us from time to time with the Securities and Exchange Commission. We caution you not to place undue reliance on the forward-looking statements contained in this presentation. All forward-looking statements are based on information currently available to us as of today, and we undertake no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.

Health Claims Disclaimer

Statements made in this presentation and appendices have not been evaluated by the Food and Drug Administration. LifeVantage products are not intended to treat, cure, prevent or mitigate any disease. The statements in this presentation are for investors’ educational purposes only.

A woman and a young boy are walking on a beach, holding hands. The woman is carrying a surfboard under her arm. They are both wearing wetsuits. The background shows the ocean and a small island in the distance.

THE COMPANY: LifeVantage (NASDAQ: LFDN)

LifeVantage is a pioneer in Nutrigenomics - a new science dedicated to cracking the human aging code.

We agree with leading researchers that extending human life is inevitable. However, we believe that in order to truly enjoy extreme longevity, we need to biohack both our physical and financial health. That is why we have combined our pioneering nutrigenomics efforts with a powerful entrepreneurial vehicle.

Our products are sold exclusively through that entrepreneurial vehicle - our network of independent distributors.

LifeVantage Factsheet



NASDAQ Ticker	LFVN	Share price ¹	\$13.37
Shares outstanding ¹	14.1 million	Float ¹	13.2 million
Market Capitalization ¹	\$188.4 million	Enterprise Value ¹	\$176.2 million
Average Daily Volume ¹	145,120	Fiscal 2018 Revenue	\$203.2 million
Cash at September 30, 2018	\$17.1 million	Fiscal 2018 Adjusted EBITDA ²	\$14.9 million
Debt at September 30, 2018	\$4.9 million	Fiscal 2018 Adjusted EPS ²	\$0.51

(1) As of January 9, 2019

(2) A reconciliation of non-GAAP measures is included in the appendix to this presentation Fiscal year ends June 30

I N D U S T R Y

TRENDS





AUGUST 25, 2017

FOX NEWS

“Nutrigenomics...is changing everything. Where we once thought we were powerless is now an area over which we have at least some control. The ability to use nutrition to affect our genes means that we're no longer at the mercy of our DNA. “



SEPTEMBER 12, 2017

THE TODAY SHOW

“The latest trend in nutrition isn't a fad diet or newly discovered supplement; it's your DNA.”

PROJECTED MARKET

NUTRIGENOMICS

“Nutrigenomics market is
expected to reach

\$17,313,500,000

by 2023.”

MARKET RESEARCH
FUTURE





L I F E V A N T A G E

ADDITIONAL TRENDS

Market trends relating to specific LifeVantage products.

ANTI-AGING

Nrf2, NRF1, TrueScience
Skin Care

2015: \$140.3 bn

2021: \$216 bn

SKIN CARE

TrueScience

2015: \$121 bn

2021: \$154 bn

NOOTROPICS (BRAIN HEALTH)

Axio, NRF1

2015: \$2.3 bn

2021: \$11.6 bn

WEIGHT LOSS

PhysIQ

2015: \$158 bn

2021: \$241 bn

HAIR CARE

HAIR CARE

2017: \$89 bn

2024: \$110 bn

TRENDS

The rise of the health activated individual

- ◆ Rapid democratization of genomic and other personalized health data is giving rise to a new wave of health-conscious individuals
- ◆ More than ever, education and understanding of one's own health is becoming widespread
- ◆ Individuals will research, measure and manage their overall health much like their personal finances
- ◆ Millennials have become a major driving force, empowered by ready access to genomic testing, health tools and a social network environment filled with influencers, all with a desire to hack the code to a healthier lifestyle

Biohacking

LifeVantage is a biohacking company. Using nutrigenomics to hack the human body for increased health.

- ◆ These trends have led to the emergence of **“Biohacking”**
 - ◆ The art of hacking your biology using nature's built-in mechanisms to stack the cards in your favor and become the best version of yourself
 - ◆ Bio-hacking is using science and personalized results to take control of and upgrade your body, your mind and your life
- ◆ Our mission is to “Bio-Hack the Aging Code” through the relentless pursuit of science-based, nutrigenomic products with the intent of helping our customers live longer, healthier lives

Premium Products



Patented

Several patents, including our initial patent "Compositions And Methods For Alleviating Inflammation And Oxidative Stress In A Mammal"

Science-backed

Protandim Studies conducted at the following institutions:
The Ohio State University
University of Colorado Denver
Colorado State University
LSU
Virginia Commonwealth University
Texas Tech University

Peer-reviewed Published Research

Research published in the following medical journals:
Free Radical Biology & Medicine
Enzyme Research
Circulation
American Journal of Physiology—Lung Cellular and Molecular Physiology



HOW WE GO TO MARKET



DIRECT SELLING CHANNEL


A large global sales channel ideally suited for our products

- ◆ Global sales of \$190 billion in 2017
- ◆ CAGR of 4% since 2014
- ◆ More than 117 million direct sellers worldwide




DIRECT SELLING (US)


PEOPLE INVOLVED IN DIRECT SELLING
(in millions)



US RETAIL SALES
(in billions)



PEOPLE INVOLVED BY AGE





L I F E V A N T A G E

ROOM FOR GROWTH

Direct selling regional sales and top 3 product categories.

North America: \$36.9 billion

- Wellness: 34%
- Cosmetics & Personal Care: 17%
- Household Goods & Durables: 14%

Europe: \$38.5 billion


- Wellness: 32%
- Cosmetics & Personal Care: 26%
- Home Improvement: 12%

South & Central America: \$27.1 billion

- Cosmetics & Personal Care: 67%
- Wellness: 14%
- Clothing & Accessories: 6%

Asia-Pacific: \$85.4 billion

- Wellness: 50%
- Cosmetics & Personal Care: 23%
- Household Goods & Durables: 11%



 Current LifeVantage Market

Source: Direct Selling News, 2017 data



WHAT IS GOING TO DRIVE GROWTH?

GROWTH OPPORTUNITIES

Geographical

Greater China expansion utilizing an e-commerce model in Mainland China
February 2018

Opened Germany September 2017

Opened Taiwan June 2018

Opened Austria September 2018

Expanding Our Distributor Base

Launched Global Customer Expansion
April 2018

Belgium

France

Ireland

Italy

New Zealand

Dominican Republic

New Products

Tools and Technologies

CROSS BORDER E-COMMERCE PROGRAM INTO MAINLAND CHINA

Entered Mainland China through an innovative e-commerce and social influencer model

- ◆ Formally launched on February 1, 2018
- ◆ Business model is not multi-level marketing
- ◆ Utilizing third party social influencers in China
- ◆ Products already approved for e-commerce



EXPANDING DISTRIBUTOR BASE

RED CARPET PROGRAM

- ◆ Recently deployed an enhanced effort to attract new experienced leaders to LifeVantage through a program focused on creating relationships with developed leaders with access to our corporate leadership team, while providing activity based incentives as they build their business
- ◆ Incentivize experienced sales leaders to attract and retain accomplished salespeople to drive our business

Enhancing the demographics and skillset of our distributor base

- ◆ Focused on enhancing distributor base by attracting a second wave of leaders who are technology adept and social commerce savvy
- ◆ History of success with similar programs, which have demonstrated significant return on investment



NEW PRODUCT INTRODUCTIONS IN FY2018 and FY2019

Vitality Stacks

- ◆ Reconfigured product strategy from single products to a regimen that creates integrated product systems
- ◆ Combining several of our powerful nutrigenomic products into a single solution that will become the basis of our bio-hacking protocol
 - ◆ Vitality Stack
 - ◆ Beauty Stack
- ◆ Introduced Vitality Stack Packets, providing convenient single-day serving size for on-the-go customers

Flagship Products Sent to Key Growth Markets

- ◆ Launched Protandims in Mexico, Thailand and Australia

New Product Launches

- ◆ FY2018 – Omega+, Protein Flavor Enhancers, TruScience Hand Cream
 - ◆ FY2019 – TrueScience Hair Care System® in October 2018
-



TrueScience Hair Care System®

Launched on October 30, 2018


- ◆ Engineered with Nrf2 ingredients
- ◆ Backed by independent market research
- ◆ Scores very well on popular app Think Dirty – targeting ingredient conscious consumers focused on clean and safe personal care products

\$89 billion global industry, growing to \$110 billion by 2024¹



Tools and Technology

ADDITIONAL EFFORTS TO DRIVE LONG TERM GROWTH



TOOLS

Utilizing machine learning to assist our distributor base in selling and empowering them with digital technology with the LifeVantage App.

F I N A N C I A L


OVERVIEW





L I F E V A N T A G E

SALES HISTORY



May 2015 New CEO

- Began to implement growth initiatives

September 2016 Disruption

- Review of cross border sales resulted in policy and procedure adjustments that interrupted sales momentum

March 2017 Management Enhancements

- Recruited experienced CFO and COO

Fiscal 2018 Initiatives

- Implemented key initiatives focused on increasing average order size, geographical expansion and distributor and customer acquisition
- Sequential and year-over-year sales growth accelerates


*Record second quarter fiscal 2019 preliminary revenue reported on January 9, 2019



L I F E V A N T A G E

GLOBAL REACH

Distribution of sales by sales area.





L I F E V A N T A G E

LAUNCHED 2019 INITIATIVES

- Continue geographical expansion, building the Greater China region with the recent launch of Taiwan
 - Opened Austria in September 2018
 - Announced intention to open France, Greece, Belgium, Ireland and Spain later in fiscal 2019
- Further expand successful Red Carpet program to attract new and experienced direct sales leaders to LifeVantage
 - Utilize PaceSetter program to further build engagement and advancement
- Build upon the LifeVantage Digital technology platform with incremental functionality and enhancements
- Continue to develop new innovative products and stacks
 - Launched True Science Hair Care System at Global Convention in October
- Strengthen current markets with further improvements to active member counts, retention and average order size
- Optimize the benefits, branding and publicity associated with LifeVantage's jersey front sponsorship of the Real Salt Lake Major League Soccer club
 - Leverage Auto-Assigned Customer Program
- Develop an IT Roadmap, evaluating core distributor and customer facing systems




L I F E V A N T A G E

AMERICAS MARKET



75% OF SALES

- Launched Protandim NRF2 in Mexico
- Successful Leadership Events
 - Global Convention event in Salt Lake City
 - Elite Academy event in Anaheim
 - Elite Academy event in Denver
 - Canada Leadership Academy in Vancouver
 - Elite Academy event in Orlando
 - Elite Academy event in Indianapolis







ASIA PACIFIC & EUROPE MARKETS

25% OF SALES

- Launched China in February 2018
- Launched Germany in September 2017
- Introduced NRF2 in Thailand
- Launched Taiwan in June 2018
- Launched Austria in September 2018
- Successful Leadership Events
 - Elite Academy event in Japan
 - European Leadership Academy event in Netherlands



Asia/Pacific & Europe Sales History





L I F E V A N T A G E

BUSINESS MODEL

(as % of revenue)	FY 2016	FY 2017	FY 2018	Long-term Target
Gross Margin ¹	83.6%	83.2%	82.4%	84.0%
Commissions and Incentives	49.9%	48.5%	48.3%	48.0%
SG&A ²	26.3%	30.6%	29.0%	24.0%
Operating Margin ³	7.3%	4.2%	5.1%	12.0%
Adjusted EBITDA Margin ³	9.5%	6.6%	7.3%	14.5%

A reconciliation of non-GAAP items is included at the appendix of this presentation

¹ Non-GAAP adjustments to FY 2018 gross margin to exclude the benefit related to a change in estimate for the accrual of import duties. A full reconciliation of FY2018 adjusted earnings are included at the end of this presentation

² Non-GAAP adjustments to FY 2016 to FY2018 SG&A to exclude expenses associated with the audit committee review, class action expenses, non-recurring legal expenses, reverse split fees, insurance reimbursement and recruiting, severance and management transition fees. A full reconciliation of FY2016 to FY2018 adjusted earnings are included at the end of this presentation

³ Non-GAAP adjustments to FY 2016 to FY2018 include the adjustments noted above. A full reconciliation of FY2016 to FY2018 adjusted earnings are included at the end of this presentation

INVESTMENT SUMMARY



Well positioned with on-trend scientific products in a growing, global sales channel

Highly efficient business model with strong cash flow and high incremental margins

Continuous focus on product innovation and international market opportunities position us for growth

Demonstrated ability to drive accelerated revenue growth



APPENDIX

Recent Operating Results Comparison



LIFEVANTAGE CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except per share data)

	Most Recent Quarter	Previous Sequential Quarter	Sequential Change	Prior Year Period	Year over Year Change
	Q1 of Fiscal 2019	Q4 of Fiscal 2018	%	Q1 of Fiscal 2018	%
Revenue, net	\$ 55,609	\$ 54,033	2.9%	\$ 49,127	13.2%
Cost of sales	9,199	8,071		8,739	
Gross profit	46,410	45,962	1.0%	40,388	14.9%
Commissions and incentives	27,785	27,069		23,409	
Selling, general and administrative	17,301	14,594		15,581	
Total operating expenses	45,086	41,663		38,990	
Operating income	1,324	4,299	(69.2%)	1,398	(5.3%)
Interest expense	(110)	(99)		(162)	
Other income (expense), net	(49)	(199)		22	
Total other income (expense)	159	(298)		(140)	
Income before income taxes	1,165	4,001		1,258	
Income tax expense	(254)	(1,009)		(441)	
Net income	911	2,992	(69.6%)	817	11.5%
EPS (Net income per share, basic)	\$ 0.07	\$ 0.21	(66.7%)	\$ 0.06	16.7%
EPS (Net income per share, diluted)	\$ 0.06	\$ 0.21	(71.4%)	\$ 0.06	0.0%
Weighted average shares, basic	13,987	14,046		13,963	
Weighted average shares, diluted	15,126	14,147		14,080	
Non-GAAP Items					
Adjusted EBITDA*	3,260	5,175	(37.0%)	2,662	22.5%
Adjusted Net Income*	1,038	2,807	(63.0%)	1,006	3.2%
Adjusted EPS (Net income per share, diluted)*	\$ 0.07	\$ 0.20	(65.0%)	\$ 0.07	0.0%

* A reconciliation of non-GAAP items, including Adjusted EBITDA, Adjusted Net Income and Adjusted Earnings per Diluted Share, is included at the appendix of this presentation

Historical Income Statements



LIFEVANTAGE CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	Fiscal Year ended June 30,			Fiscal 2018	Fiscal 2019
	2016	2017	2018	Q1 18	Q1 19
(In thousands, except per share data)					
	(as revised)				
Revenue, net	\$ 206,540	\$ 199,489	\$ 203,204	\$ 49,127	\$ 55,609
Cost of sales	33,932	33,456	34,848	8,739	9,199
Gross profit	172,608	166,033	168,356	40,388	46,410
Commissions and incentives	103,120	96,662	98,193	23,409	27,785
Selling, general and administrative	56,074	64,922	59,840	15,581	17,301
Total operating expenses	159,194	161,584	158,033	38,990	45,086
Operating income	13,414	4,449	10,323	1,398	1,324
Interest expense	(3,321)	(570)	(456)	(162)	(110)
Other income (expense), net	(1,409)	(969)	(319)	22	(49)
Total other income (expense)	(4,730)	(1,539)	(775)	(140)	(159)
Income before income taxes	8,684	2,910	9,548	1,258	1,165
Income tax expense	(2,578)	(1,302)	(3,787)	(441)	(254)
Net income	6,106	1,608	5,761	817	911
EPS (Net income per share, basic)	\$ 0.44	\$ 0.12	\$ 0.41	\$ 0.06	\$ 0.07
EPS (Net income per share, diluted)	\$ 0.42	\$ 0.11	\$ 0.41	\$ 0.06	\$ 0.06
Weighted average shares, basic	13,730	13,881	13,992	13,963	13,987
Weighted average shares, diluted	14,531	14,118	14,136	14,080	15,126
Non-GAAP Items					
Adjusted EBITDA*	19,650	13,087	14,910	2,662	3,260
Adjusted Net Income*	9,235	3,932	7,194	1,006	1,038
Adjusted EPS (Net income per share, diluted)*	\$ 0.64	\$ 0.27	\$ 0.51	\$ 0.07	\$ 0.07

* A reconciliation of non-GAAP items, including Adjusted EBITDA, Adjusted Net Income and Adjusted Earnings per Diluted Share, is included at the appendix of this presentation

Historical Balance Sheet and Cash Flows



LIFEVANTAGE CORPORATION AND SUBSIDIARIES SUMMARIZED BALANCE SHEET AND CASH FLOW METRICS

(Unaudited, in thousands, except per share data)

	As of June 30,			Quarter Ended September 30,	
	2016	2017	2018	2017	2018
Cash and Cash Equivalents	\$ 7,883	\$ 11,458	\$ 16,652	\$ 12,288	\$ 17,123
Current Portion of Long-term Debt	2,000	2,000	2,000	2,000	2,000
Long-term Debt, Net of Discount	7,409	5,440	3,412	4,948	2,921
Total Debt	9,409	7,440	5,412	6,948	4,921
Net Cash (Cash and equivalents less total Debt)	(1,526)	4,018	11,240	5,340	12,202
Net Cash per share, diluted	\$ (0.11)	\$ 0.28	\$ 0.80	\$ 0.38	\$ 0.81
Total Assets	50,855	45,249	51,142	44,793	51,921
Total Stockholders' Equity	10,649	14,527	21,947	15,772	23,531
Book Value per share, diluted	\$ 0.73	\$ 1.03	\$ 1.55	\$ 1.12	\$ 1.56

(Unaudited, in thousands, except per share data)

	Fiscal Year ended June 30,			Quarter ended September 30,	
	2016	2017	2018	2017	2018
Net Cash Provided by Operating Activities	\$ 6,036	\$ 6,597	\$ 13,256	\$ 2,503	\$ 2,366
Capital Expenditures	562	1,055	4,649	1,176	86
Free Cash Flow	5,474	5,542	8,607	1,327	2,280
Free Cash Flow per share, diluted	\$ 0.38	\$ 0.39	\$ 0.61	\$ 0.09	\$ 0.15

Non-GAAP Reconciliations



LIFEVANTAGE CORPORATION AND SUBSIDIARIES

Adjusted Net Income

(Unaudited, in thousands, except per share data)

	Fiscal Year				Fiscal 2018	Fiscal 2018	Fiscal 2019
	2015	2016	2017	2018	Q1	Q4	Q1
Period ended	6/30/15	6/30/16	6/30/17	6/30/17	9/30/17	6/30/18	9/30/18
GAAP Net income	\$7,126	\$6,106	\$1,608	\$5,761	\$817	\$2,992	\$911
Adjustments:							
Recall related expenses	(2,000)	—	—	—	—	—	—
Executive team recruiting and transition expenses	880	928	744	207	44	—	—
Audit committee independent review expenses	—	—	2,742	—	—	—	—
Class-action lawsuit expenses	—	—	170	659	196	317	3
Executive Team Severance Expenses, Net	565	632	39	374	—	314	(79)
Reverse Split Fees	—	159	—	—	—	—	—
Write-Off of Deferred Debt Offering Costs	—	1,544	—	—	—	—	—
Write-off of intangible assets	—	—	350	—	—	—	—
Jenkon Write-Off	—	1,186	—	—	—	—	—
Other nonrecurring legal and accounting expenses	—	—	160	51	51	—	238
Insurance reimbursement	—	—	—	(425)	—	(425)	—
Change in estimate of accrued import liabilities	—	—	—	(863)	—	(863)	—
Tax impact of adjustments	184	(1,320)	(1,881)	(42)	(102)	166	(35)
Tax expense impact of revaluation of deferred tax assets	—	—	—	1,472	—	306	—
Total adjustments, net of tax	(371)	3,129	2,324	1,433	189	(185)	127
Non-GAAP Net Income:	6,755	9,235	3,932	7,194	1,006	2,807	1,038
Diluted earnings per share, as reported	0.50	0.42	0.11	0.41	0.06	0.21	0.06
Total adjustments, net of tax	(0.02)	0.22	0.16	0.10	0.01	(0.01)	0.01
Diluted earnings per share, as adjusted	0.48	0.64	0.27	0.51	0.07	0.20	0.07

Non-GAAP Reconciliations



LIFEVANTAGE CORPORATION AND SUBSIDIARIES

EBITDA and Adjusted EBITDA

(Unaudited, in thousands)

	Fiscal Year				Fiscal 2018	Fiscal 2018	Fiscal 2019
	2015	2016	2017	2018	Q1	Q4	Q1
Period ended	6/30/15	6/30/16	6/30/17	6/30/18	9/30/17	6/30/18	9/30/18
GAAP Net income	\$7,126	\$6,106	\$1,608	\$5,761	\$817	\$2,992	\$911
Interest Expense	3,087	3,321	570	456	162	99	110
Provision for income taxes	3,527	2,578	1,302	3,787	441	1,009	254
Depreciation and amortization	2,285	1,895	1,643	1,325	350	383	441
Non-GAAP EBITDA:	16,025	13,900	5,123	11,329	1,770	4,483	1,716
Adjustments:							
Stock compensation expense	1,806	2,621	2,647	3,196	623	1,087	1,333
Other (income) expense, net	159	1,409	969	319	(22)	199	49
Other adjustments	(554)	1,720	4,348	66	291	(594)	162
Total adjustments	1,411	5,750	7,964	3,581	892	692	1,544
Non-GAAP Adjusted EBITDA	17,436	19,650	13,087	14,910	2,662	5,175	3,260